Understanding how certain cells contribute to lung scarring in pulmonary fibrosis
Official title: Frontiers at the edge: Subpleural fibroblasts orchestrate pulmonary fibrosis progression
Funded at University of California, San Diego · NIH-11094718 · Data updated 2026-11-12
This study is looking into how certain cells in the lungs contribute to the worsening of idiopathic pulmonary fibrosis (IPF), with the goal of finding better ways to diagnose and treat this lung condition for patients like you.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | June 1, 2024 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $153,130 |
| NIH project number | 5K99HL171830-02 |
| Project ID | NIH-11094718 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis or those at risk of developing this condition.
✕Less likely to help
Patients with other forms of lung disease unrelated to pulmonary fibrosis may not benefit from this research.
What this research studies
This research investigates idiopathic pulmonary fibrosis (IPF), a severe lung condition characterized by the formation of scar tissue. The study focuses on the role of specific fibroblast cells located at the edges of the lungs, which may drive the progression of fibrosis. Using advanced techniques like lineage tracing and single-cell sequencing, researchers aim to uncover the biological signals that initiate and exacerbate this disease. By identifying these mechanisms, the research seeks to improve early diagnosis and treatment options for patients with IPF.
Why it matters
Potential benefit: If successful, this research could lead to better understanding and treatment options for patients suffering from pulmonary fibrosis.
How similar studies have gone: Previous research has shown promising results in understanding the cellular mechanisms of fibrosis, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of California, San Diego
La Jolla, United States Active
Researchers
- Principal investigator: Xu, Le — University of California, San Diego
- Study coordinator: Xu, Le
Related research
Other NIH-funded projects on the same topics.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
-
Alveolar Cell Dysfunction in Pulmonary Fibrosis: Using SFTPC Mutations to Find New Targets
This grant explores how rare SFTPC mutations in alveolar cells may drive IPF and seeks new molecular targets to improve treatment.
-
Iron and scar-forming cells in the lungs (IPF)
Researchers are exploring how iron in the lungs may drive the scarring seen in idiopathic pulmonary fibrosis and whether this could lead to new therapies.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Role of lactate transporters in lung scarring
Aims to see if blocking lactate transporters can slow or stop scar-forming cells from thickening the lungs in people with fibrotic lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.